State of New Jersey Common Pension Fund D Reduces Stake in CVS Health Corporation $CVS

State of New Jersey Common Pension Fund D reduced its stake in CVS Health Corporation (NYSE:CVS) by 1.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 434,295 shares of the pharmacy operator’s stock after selling 7,291 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in CVS Health were worth $34,466,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in CVS. Sei Investments Co. grew its holdings in CVS Health by 17.4% in the 2nd quarter. Sei Investments Co. now owns 905,715 shares of the pharmacy operator’s stock valued at $62,474,000 after buying an additional 134,535 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in CVS Health by 1.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,121,377 shares of the pharmacy operator’s stock valued at $77,353,000 after buying an additional 13,329 shares in the last quarter. Treasurer of the State of North Carolina grew its holdings in CVS Health by 1.3% in the 2nd quarter. Treasurer of the State of North Carolina now owns 585,073 shares of the pharmacy operator’s stock valued at $40,358,000 after buying an additional 7,588 shares in the last quarter. HUB Investment Partners LLC grew its holdings in CVS Health by 25.0% in the 2nd quarter. HUB Investment Partners LLC now owns 15,063 shares of the pharmacy operator’s stock valued at $1,039,000 after buying an additional 3,011 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its stake in shares of CVS Health by 8.0% in the 2nd quarter. Alliancebernstein L.P. now owns 1,609,404 shares of the pharmacy operator’s stock valued at $111,017,000 after purchasing an additional 119,439 shares during the last quarter. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS won enterprise- and customer-facing AI awards, highlighting scaled AI deployments that could improve customer experience and operational efficiency. CVS Health’s Award Winning AI Raises Questions For Investors To Watch
• Positive Sentiment: CVS launched an AI health platform in partnership with Google Cloud, a strategic move that can accelerate digital services and pharmacy/clinic integration. CVS launches AI health platform with Google Cloud partnership
• Positive Sentiment: Barron’s published a bullish take arguing CVS is no longer a “value trap,” which can support investor sentiment and longer-term positioning despite near-term noise. CVS Earnings Are Coming. Why the Stock Is No Longer a Value Trap.
• Positive Sentiment: Steve Nelson, President of Aetna (a CVS company), was named to Health Catalyst’s board — a sign of CVS leadership visibility in health-tech partnerships and ecosystem influence. Health Catalyst Appoints Steve Nelson, President of Aetna, to Its Board of Directors
• Neutral Sentiment: Cigna’s exit from the ACA market and stronger-than-expected outlook for 2026 is industry news that could change exchange dynamics and PBM volumes — relevant but indirect for CVS. Cigna Exits Obamacare Market As PBM Profit Drops 28%
• Neutral Sentiment: Coverage of Viatris’s upcoming results and beat probability is being circulated (industry context for pharma supply/competitive backdrop). Viatris (VTRS) Earnings Expected to Grow: Should You Buy?
• Neutral Sentiment: Zacks and other sites note heightened investor interest/searches in CVS, which often precedes volatility around earnings and newsflow. Investors Heavily Search CVS Health Corporation (CVS): Here is What You Need to Know
• Negative Sentiment: Analyst previews from Zacks/Yahoo warn CVS may report a decline in earnings and lack the key setup for an earnings beat; that caution pressures the stock ahead of results. Analysts Estimate CVS Health (CVS) to Report a Decline in Earnings: What to Look Out for
• Negative Sentiment: A Zacks Q1 preview highlights benefits pressure and elevated costs — noting health services growth may offset but not fully eliminate margin risk this quarter. CVS Q1 Earnings Preview: Health Services Likely to Lead Performance

CVS Health Price Performance

CVS opened at $83.44 on Friday. The stock’s 50-day moving average price is $76.32 and its 200 day moving average price is $77.97. CVS Health Corporation has a 12-month low of $58.35 and a 12-month high of $85.15. The company has a current ratio of 0.84, a quick ratio of 0.63 and a debt-to-equity ratio of 0.80. The firm has a market cap of $106.93 billion, a price-to-earnings ratio of 60.46, a PEG ratio of 0.88 and a beta of 0.51.

CVS Health (NYSE:CVS) last posted its earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.09. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The firm had revenue of $105.69 billion for the quarter, compared to analyst estimates of $103.67 billion. During the same quarter in the prior year, the company earned $1.19 EPS. CVS Health’s revenue was up 8.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. As a group, sell-side analysts expect that CVS Health Corporation will post 7.14 earnings per share for the current year.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, May 4th. Investors of record on Thursday, April 23rd will be paid a dividend of $0.665 per share. The ex-dividend date of this dividend is Thursday, April 23rd. This represents a $2.66 annualized dividend and a yield of 3.2%. CVS Health’s dividend payout ratio is presently 192.75%.

Analysts Set New Price Targets

Several equities analysts have recently commented on CVS shares. Robert W. Baird upped their price target on CVS Health from $92.00 to $94.00 and gave the company an “outperform” rating in a research note on Wednesday, April 15th. Wolfe Research decreased their price target on CVS Health from $100.00 to $97.00 and set an “outperform” rating on the stock in a research note on Monday, March 2nd. TD Cowen reaffirmed a “buy” rating on shares of CVS Health in a research note on Friday, March 13th. Argus decreased their price target on CVS Health from $91.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday, January 28th. Finally, Piper Sandler decreased their price target on CVS Health from $101.00 to $99.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 31st. Twenty analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $95.05.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.